Related Experiment Videos
Venous thromboembolism and escitalopram
Asli Kurne1, Aygun Ertugrul, A Elif Anil Yağcioğlu
1Department of Psychiatry, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.
General Hospital Psychiatry
|November 30, 2004
Summary
Selective serotonin reuptake inhibitors (SSRIs) may increase thrombosis risk. This report details a venous thromboembolism case linked to escitalopram, suggesting a potential dual effect on platelet function.
Area of Science:
- Neuroscience
- Pharmacology
- Hematology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are first-line depression treatments known for a good side-effect profile.
- Escitalopram, a newer SSRI, is generally well-tolerated with rare serious side effects.
- Previous studies suggest SSRIs may affect platelet function, potentially increasing bleeding risk.
Observation:
- This report presents a rare case of venous thromboembolism (VTE).
- The VTE occurred in a patient with psychotic depression treated with escitalopram.
- The patient had no significant pre-existing risk factors for thrombosis.
Findings:
- SSRIs might exert a dual effect on platelet function.
- An early effect of SSRI use may involve an increased tendency for thrombosis.
- Late effects, after repeated dosing, might lead to an increased tendency for bleeding.
Implications:
- This case highlights a potential, previously unreported association between escitalopram and thrombosis.
- Further research is needed to understand the dual hemostatic effects of SSRIs.
- Clinicians should consider the potential for both bleeding and clotting complications with SSRI use.